The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?

J Exp Clin Cancer Res. 2022 Sep 16;41(1):276. doi: 10.1186/s13046-022-02484-1.

Abstract

The extracellular matrix (ECM) is an important component of the tumor microenvironment (TME), having several important roles related to the hallmarks of cancer. In cancer, multiple components of the ECM have been shown to be altered. Although most of these alterations are represented by the increased or decreased quantity of the ECM components, changes regarding the functional alteration of a particular ECM component or of the ECM as a whole have been described. These alterations can be induced by the cancer cells directly or by the TME cells, with cancer-associated fibroblasts being of particular interest in this regard. Because the ECM has this wide array of functions in the tumor, preclinical and clinical studies have assessed the possibility of targeting the ECM, with some of them showing encouraging results. In the present review, we will highlight the most relevant ECM components presenting a comprehensive description of their physical, cellular and molecular properties which can alter the therapy response of the tumor cells. Lastly, some evidences regarding important biological processes were discussed, offering a more detailed understanding of how to modulate altered signalling pathways and to counteract drug resistance mechanisms in tumor cells.

Keywords: Cancer; Drug resistance; Extracellular matrix; Tumour microenvironment.

Publication types

  • Review

MeSH terms

  • Drug Resistance*
  • Extracellular Matrix* / pathology
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Tumor Microenvironment